Portola Pharma (PTLA) Tops Q1 EPS by 26c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
- Exclusive-Silver Lake in talks to buy Workday, sources say
- Crude Inventory Rose 17.2 Million Barrels Last Week - EIA
- Citi agrees to acquire rewards platform Kard Financial
- Burry doubles down on Nebius short after stock surges 34% on earnings
- Total darkness, then sunset as full eclipse wows spectators in Spain
Portola Pharmaceuticals Reports First Quarter 2018 Financial Results and Provides Corporate Update
May 9, 2018 4:05 PM EDT-- Conference Call Today at 4:30 p.m. ET --
SOUTH SAN FRANCISCO, Calif., May 09, 2018 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (Nasdaq: PTLA) today reported financial results for the three months ended March 31, 2018 and provided a corporate update.
We achieved several major manufacturing and regulatory milestones this past year, including last weeks U.S. approval of Andexxa®. We are now concentrating the Companys efforts on the successful launch of Andexxa and Bevyxxa®, which both have the potential to impact public health... More
